Live‐attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation
Pediatric Transplantation · 2024
DOI: 10.1111/petr.14687 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Anne Keutler und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany. Hauptthemen laut MEDLINE: Mumps, Liver Transplantation, Rubella, Measles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Infections are a serious short‐ and long‐term problem after pediatric organ transplantation. In immunocompromised patients, they can lead to transplant rejection or a severe course with a sometimes fatal outcome. Vaccination is an appropriate means of reducing morbidity and mortality caused by vaccine‐preventable diseases. Unfortunately, due to the disease or its course, it is not always possible to establish adequate vaccine protection against live‐attenuated viral vaccines (LAVVs) prior to transplantation. LAVVs such as measles, mumps, and rubella (MMR) are still contraindicated in solid organ transplant recipients receiving immunosuppressive therapy (IST), thus creating a dilemma.
Aim
This review discusses whether, when, and how live‐attenuated MMR vaccines can be administered effectively and safely to pediatric liver transplant recipients based on the available data. Material and Methods We searched PubMed for literature on live‐attenuated MMR vaccination in pediatric liver transplantation (LT).
Results
Nine prospective observational studies and three retrospective case series were identified in which at least 833 doses of measles vaccine were administered to 716 liver transplant children receiving IST. In these selected patients, MMR vaccination was well tolerated and no serious adverse reactions to the vaccine were observed. In addition, an immune response to the vaccine was demonstrated in patients receiving IST.
Conclusion
Due to inadequate vaccine protection in this high‐risk group, maximum efforts must be made to ensure full immunization. MMR vaccination could also be considered for unprotected patients after LT receiving IST following an individual risk assessment, as severe harm from live vaccines after liver transplantation has been reported only very rarely. To this end, it is important to establish standardized and simple criteria for the selection of suitable patients and the administration of the MMR vaccine to ensure safe use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
- University Children's Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Gastroenterology and Nutrition, University Children's Hospital Zurich, Zurich, Switzerland.
ORCID-Profile: Elke Lainka, Carsten Posovszky
Zitieren
APA
Keutler, A., Lainka, E., & Posovszky, C. (2024). Live‐attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.14687
Vancouver
Keutler A, Lainka E, Posovszky C. Live‐attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation. Pediatric Transplantation. 2024. doi:10.1111/petr.14687
BibTeX
@article{Keutler2024,
author = {Keutler, Anne and Lainka, Elke and Posovszky, Carsten},
title = {Live‐attenuated vaccination for measles, mumps, and rubella in pediatric liver transplantation},
journal = {Pediatric Transplantation},
year = {2024},
doi = {10.1111/petr.14687}
}
EUVIMED